AP-101 in Familial and Sporadic ALS

Phase 1, open-label trial of AP-101 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AL-S Pharma AG. Primary endpoints: Number of Participants With One or More Non-Serious Adverse Events or Any Serious Adverse Events and Number of participants with abnormalities in vital signs, clinical laboratory assessments, physical or neurological examinations, or electrocardiograms. Status: unknown.